PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Clinical trial NCT02049593 · COMPLETED
Trial details
- NCT number
- NCT02049593
- Sponsor
- Jonsson Comprehensive Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-06-12
- Primary completion
- 2019-10-07
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.